Coronavirus Update: Lilly’s Antibody Plus Remdesivir Trial Abandoned

Other Lilly and NIH Studies Continue

Combination of antibody therapy and Gilead's Veklury fails to show potential in patients with advanced disease.  

Waiting In Line
Queens, New York: voters observe social distancing rules as they stand in line to take part in early voting for the US election on 3 November.

Eli Lilly has confirmed that the ACTIV-3 trial of its antibody therapy bamlanivimab (previously known as LY-CoV555) in combination with Gilead’s Veklury (remdesivir) in advanced COVID-19 has been abandoned after it showed no signs of helping patients.

ACTIV-3 was stopped two weeks ago by its sponsors, the National Institute of Allergy and Infectious Diseases (NIAID), part of...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Business

More from Scrip